Equities

TNF Pharmaceuticals Inc

TNF Pharmaceuticals Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.25
  • Today's Change-0.02 / -1.57%
  • Shares traded29.33k
  • 1 Year change-91.13%
  • Beta2.1828
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects TNF Pharmaceuticals Inc share price to rise to 4.00 in the next year from the last price of 1.25.
High220.0%4.00
Med220.0%4.00
Low220.0%4.00

Earnings history & estimates in USD

On Apr 03, 2018, TNF Pharmaceuticals Inc reported 4th quarter 2017 losses of -2,304.00 per share.
Average growth rate-58.17%
TNF Pharmaceuticals Inc reported annual 2017 losses of -6,105.60 per share on Apr 03, 2018.
Average growth rate-31.61%
More ▼

Revenue history & estimates in USD

Akers Biosciences, Inc. had 4th quarter 2017 revenues of 1.39m. This missed the 2.10m estimate of the one analyst following the company. The same period last year the company did not report revenues.
Average growth rate+30.95%
Akers Biosciences, Inc. had revenues for the full year 2017 of 3.93m. This was 32.73% above the prior year's results.
Average growth rate+6.83%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.